BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 29735542)

  • 1. PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent.
    Song C; Wang L; Wu X; Wang K; Xie D; Xiao Q; Li S; Jiang K; Liao L; Yates JR; Lee JD; Yang Q
    Cancer Res; 2018 May; 78(10):2475-2489. PubMed ID: 29735542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
    Poole CJ; Lodh A; Choi JH; van Riggelen J
    Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylcytosine dioxygenase ten-eleven translocation 2 enhances lipopolysaccharide-induced cytokine expression in human dental pulp cells by regulating MyD88 hydroxymethylation.
    Wang X; Feng Z; Li Q; Yi B; Xu Q
    Cell Tissue Res; 2018 Aug; 373(2):477-485. PubMed ID: 29654353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma.
    Gong F; Guo Y; Niu Y; Jin J; Zhang X; Shi X; Zhang L; Li R; Chen L; Ma RZ
    Oncotarget; 2017 Jan; 8(1):315-328. PubMed ID: 27852070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PML::RARA and GATA2 proteins interact via DNA templates to induce aberrant self-renewal in mouse and human hematopoietic cells.
    Katerndahl CDS; Rogers ORS; Day RB; Xu Z; Helton NM; Ramakrishnan SM; Miller CA; Ley TJ
    Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2317690121. PubMed ID: 38648485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX.
    Ko M; An J; Bandukwala HS; Chavez L; Aijö T; Pastor WA; Segal MF; Li H; Koh KP; Lähdesmäki H; Hogan PG; Aravind L; Rao A
    Nature; 2013 May; 497(7447):122-6. PubMed ID: 23563267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TET2-Mediated Spatiotemporal Changes of 5-Hydroxymethylcytosine During Organogenesis in the Late Mouse Fetus.
    Li X; Xie F; Jin J; Wu Y; Luo Z; Zhang F; Zhang S; Chen D; Liu A
    Anat Rec (Hoboken); 2019 Jun; 302(6):954-963. PubMed ID: 30369084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia.
    Tong Q; You H; Chen X; Wang K; Sun W; Pei Y; Zhao X; Yuan M; Zhu H; Luo Z; Zhang Y
    Nucleic Acids Res; 2018 Apr; 46(7):3284-3297. PubMed ID: 29554366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TET2 is a component of the estrogen receptor complex and controls 5mC to 5hmC conversion at estrogen receptor cis-regulatory regions.
    Broome R; Chernukhin I; Jamieson S; Kishore K; Papachristou EK; Mao SQ; Tejedo CG; Mahtey A; Theodorou V; Groen AJ; D'Santos C; Balasubramanian S; Farcas AM; Siersbæk R; Carroll JS
    Cell Rep; 2021 Feb; 34(8):108776. PubMed ID: 33626359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia.
    Nichol JN; Galbraith MD; Kleinman CL; Espinosa JM; Miller WH
    Cell Rep; 2016 Mar; 14(12):2938-49. PubMed ID: 26997274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
    He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
    Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.
    Puig I; Tenbaum SP; Chicote I; Arqués O; Martínez-Quintanilla J; Cuesta-Borrás E; Ramírez L; Gonzalo P; Soto A; Aguilar S; Eguizabal C; Caratù G; Prat A; Argilés G; Landolfi S; Casanovas O; Serra V; Villanueva A; Arroyo AG; Terracciano L; Nuciforo P; Seoane J; Recio JA; Vivancos A; Dienstmann R; Tabernero J; Palmer HG
    J Clin Invest; 2018 Aug; 128(9):3887-3905. PubMed ID: 29944140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TET2 is involved in DNA hydroxymethylation, cell proliferation and inflammatory response in keratinocytes.
    Liu X; Wang X; Liu N; Zhu K; Zhang S; Duan X; Huang Y; Jin Z; Jaypaul H; Wu Y; Chen H
    Mol Med Rep; 2020 Apr; 21(4):1941-1949. PubMed ID: 32319620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
    Wang Y; Xiao M; Chen X; Chen L; Xu Y; Lv L; Wang P; Yang H; Ma S; Lin H; Jiao B; Ren R; Ye D; Guan KL; Xiong Y
    Mol Cell; 2015 Feb; 57(4):662-673. PubMed ID: 25601757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TET2 interactors and their links to hematological malignancies.
    Pan F; Weeks O; Yang FC; Xu M
    IUBMB Life; 2015 Jun; 67(6):438-45. PubMed ID: 26099018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tet methylcytosine dioxygenase 2 inhibits atherosclerosis via upregulation of autophagy in ApoE-/- mice.
    Peng J; Yang Q; Li AF; Li RQ; Wang Z; Liu LS; Ren Z; Zheng XL; Tang XQ; Li GH; Tang ZH; Jiang ZS; Wei DH
    Oncotarget; 2016 Nov; 7(47):76423-76436. PubMed ID: 27821816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
    Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
    Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of PML-I in reformation of PML nuclear bodies in acute promyelocytic leukemia cells by leptomycin B.
    Wang C; Su L; Shao YM; Chen WZ; Bu N; Hao R; Ma LY; Hussain L; Lu XY; Wang QQ; Naranmandura H
    Toxicol Appl Pharmacol; 2019 Dec; 384():114775. PubMed ID: 31669778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway.
    Neri F; Dettori D; Incarnato D; Krepelova A; Rapelli S; Maldotti M; Parlato C; Paliogiannis P; Oliviero S
    Oncogene; 2015 Aug; 34(32):4168-76. PubMed ID: 25362856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
    Zhu G
    Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.